By Anna C. Greene, PhD, NETRF Chief Scientific Officer In recent years, you may have seen headlines and commentaries suggesting that neuroendocrine cancers are “no
By Anna C. Greene, PhD, NETRF Chief Scientific Officer A new open-access review article in Virchows Archiv, “Novel concepts of cell-of-origin in neuroendocrine neoplasms,” by
Jamie Metzl is a writer and technology/health care futurist who regularly speaks to the medical industry on the future of health care. When Jamie’s father,
The Neuroendocrine Tumor Research Foundation (NETRF) today announced its latest round of neuroendocrine cancer research grant recipients. The thirteen investigators receiving awards are pursuing innovative,
In November 2025, Drew Greenberg marked his Bar Mitzvah in a way that moved everyone who heard his story. At just 13 years old, Drew
By Anna C. Greene, PhD, NETRF Chief Scientific Officer At the Neuroendocrine Tumor Research Foundation (NETRF), we often hear a familiar story: symptoms that don’t
By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic®, Wegovy®, and Mounjaro®, known as GLP-1 receptor agonists, are now widely used to treat
By Anna Greene, PhD, NETRF Chief Scientific Officer Each year, the Margie & Robert E. Petersen NETRF Research Symposium brings together leading scientists, clinicians, and
NETRF CEO Elyse Gellerman, Chief Scientific Officer Anna Greene, and Director of Patient Education Jessica Thomas joined hundreds of neuroendocrine cancer specialists and patient advocates
A recent review published in the Journal of Oncology Practice explores how patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) view the use and timing of radioligand